Biomea Fusion Inc
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modif… Read more
Biomea Fusion Inc (BMEA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.780x
Based on the latest financial reports, Biomea Fusion Inc (BMEA) has a cash flow conversion efficiency ratio of -0.780x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.18 Million) by net assets ($15.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biomea Fusion Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Biomea Fusion Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Biomea Fusion Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomea Fusion Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Horizon Minerals Ltd
AU:HRZ
|
-0.107x |
|
Bursa De Valori Bucuresti SA
RO:BVB
|
0.021x |
|
Visiomed Group SA
PINK:VMDGF
|
-0.003x |
|
Coya Therapeutics, Inc. Common Stock
NASDAQ:COYA
|
-0.041x |
|
Oxford Bank Corporation
PINK:OXBC
|
-0.028x |
|
Genelux Corporation Common Stock
NASDAQ:GNLX
|
-0.354x |
|
Licogi 16 JSC
VN:LCG
|
N/A |
|
Synergy Innovation Co. Ltd
KQ:048870
|
0.039x |
Annual Cash Flow Conversion Efficiency for Biomea Fusion Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Biomea Fusion Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $51.57 Million | $-119.89 Million | -2.325x | -307.31% |
| 2023-12-31 | $169.24 Million | $-96.59 Million | -0.571x | +0.75% |
| 2022-12-31 | $108.54 Million | $-62.42 Million | -0.575x | -190.12% |
| 2021-12-31 | $178.78 Million | $-35.44 Million | -0.198x | +77.02% |
| 2020-12-31 | $5.17 Million | $-4.46 Million | -0.863x | -101.42% |
| 2019-12-31 | $-21.00K | $-1.28 Million | 60.905x | -- |